We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Esperion Therapeutics (ESPR) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Esperion Therapeutics (ESPR - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Esperion Therapeutics is one of 1183 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Esperion Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ESPR's full-year earnings has moved 4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ESPR has moved about 26.6% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -16.1% on a year-to-date basis. As we can see, Esperion Therapeutics is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is TransMedics (TMDX - Free Report) . The stock is up 214.7% year-to-date.
Over the past three months, TransMedics' consensus EPS estimate for the current year has increased 17.5%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Esperion Therapeutics belongs to the Medical - Drugs industry, a group that includes 218 individual companies and currently sits at #95 in the Zacks Industry Rank. This group has lost an average of 29.9% so far this year, so ESPR is performing better in this area.
In contrast, TransMedics falls under the Medical - Instruments industry. Currently, this industry has 103 stocks and is ranked #92. Since the beginning of the year, the industry has moved -27.1%.
Investors interested in the Medical sector may want to keep a close eye on Esperion Therapeutics and TransMedics as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Esperion Therapeutics (ESPR) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Esperion Therapeutics (ESPR - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Esperion Therapeutics is one of 1183 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Esperion Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ESPR's full-year earnings has moved 4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ESPR has moved about 26.6% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -16.1% on a year-to-date basis. As we can see, Esperion Therapeutics is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is TransMedics (TMDX - Free Report) . The stock is up 214.7% year-to-date.
Over the past three months, TransMedics' consensus EPS estimate for the current year has increased 17.5%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Esperion Therapeutics belongs to the Medical - Drugs industry, a group that includes 218 individual companies and currently sits at #95 in the Zacks Industry Rank. This group has lost an average of 29.9% so far this year, so ESPR is performing better in this area.
In contrast, TransMedics falls under the Medical - Instruments industry. Currently, this industry has 103 stocks and is ranked #92. Since the beginning of the year, the industry has moved -27.1%.
Investors interested in the Medical sector may want to keep a close eye on Esperion Therapeutics and TransMedics as they attempt to continue their solid performance.